Conference presentations
Posters and oral presentations given at scientific meetings.
All publications and presentations
- PresentationTherapeutic benefits of MSC-NTF (NurOwn®) exosomes in acute lung injury models 2021 NYSCF Conference View source
- PresentationCSF biomarker correlations with primary outcome in NurOwn® Phase 3 clinical trial 2021 Annual NEALS Meeting View source
- PresentationPhase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in progressive multiple sclerosis 2019 Annual CMSC Meeting View source
- PresentationMolecular characterization of VEGF secretion by MSC-NTF cells (NurOwn®): therapeutic implications in ALS 2019 Annual AAN Meeting View source
- PresentationModulation of CSF caspase-3 in MSC-NTF cells (NurOwn®) in a Phase 2 ALS study: correlations with CSF biomarkers and clinical response 2019 Annual AAN Meeting View source
- PresentationA systematic review of enrichment strategies for current clinical trials in ALS International Symposium on ALS/MND View source
- PresentationMicroRNA changes in the NurOwn® Phase 2 ALS randomized clinical trial: relationship to neuroprotection and innate immunity Annual NEALS Conference View source
- PresentationModulation of CSF miRNAs in ALS Phase 2 study participants treated with MSC-NTF cells (NurOwn®) Annual AAN Meeting View source
- PresentationNurOwn® Phase 2 ALS trial: ALSFRS-R improvement is reflected in subscale domains Annual AAN Meeting View source
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.